Innovent's IBI302 Phase 3 Data Shows Promise for Extended AMD Treatment

Event summary

  • Innovent Biologics' Phase 3 STAR study of efdamrofusp alfa (IBI302) met its primary endpoint, demonstrating non-inferiority to aflibercept in vision improvement for nAMD patients.
  • Approximately 72.8% of patients in the IBI302 group achieved a Q16W dosing interval, with 56.3% showing no disease activity at Week 24, suggesting potential for Q20W dosing.
  • The study enrolled 600 participants, with 65% being treatment-naïve, and showed a 50% lower incidence of macular atrophy (MA) with IBI302 compared to aflibercept.
  • The study's principal investigator, Professor Xiaodong Sun, highlighted the potential of IBI302 to alleviate the treatment burden on patients through extended dosing intervals.

The big picture

Innovent's success with IBI302 represents a significant step forward in addressing the challenges of nAMD treatment, which often requires frequent and burdensome intravitreal injections. The ability to extend dosing intervals while maintaining efficacy and potentially reducing MA incidence could significantly improve patient quality of life and adherence. This development also underscores the growing trend towards multi-target therapies in ophthalmology and the increasing importance of domestically developed innovative drugs in the Chinese market.

What we're watching

Regulatory Approval
The speed of Innovent's NDA submission and subsequent approval in China will be a key indicator of market access and commercial potential for IBI302.
Market Adoption
Whether physicians and patients will embrace the extended dosing interval offered by IBI302, and its impact on patient adherence, remains to be seen.
MA Inhibition
The long-term 2-year data on macular atrophy inhibition will be crucial in establishing a differentiated clinical profile for IBI302 and justifying premium pricing.

Related topics

Drug Development